🇺🇸 FDA
Pipeline program

BZ019

XY2019028-EC-1

Phase 1 mab active

Quick answer

BZ019 for Large B-cell Lymphoma is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Large B-cell Lymphoma
Phase
Phase 1
Modality
mab
Status
active

Clinical trials